This is a pilot study to investigate if the extended release formulation of WD-1603 generates
anticipated plasma concentration profile. The study is an open-label, sequential, 3-way
crossover study to evaluate if WD-1603 generates anticipated plasma levodopa exposure
compared to Sinemet IR tablets in healthy subjects. The study comprises of a medical
Screening visit, three 2-night (3-day) Treatment periods, 2 outpatient visits, and a
Follow-up visit. Study drug administration in each Treatment period is separated by a washout
interval of 5 days. The Follow-up visit will occur approximately 7 days (±1) following the
last study drug administration. The duration of subject participation, including screening,
is approximately 6 weeks.
Phase:
Phase 1
Details
Lead Sponsor:
Hong Kong WD Pharmaceutical Co., Limited
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa